Volume 13, Issue 49 (12-2022)
NCMBJ 2022, 13(49): 23-34 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Zandi A, Abbas Tabar Ahangar H, Saffar A. Investigation of PVA / GT / Fe3O4 nanocomposite for targeted delivery of HCQ drug. NCMBJ 2022; 13 (49) :23-34
URL: http://ncmbjpiau.ir/article-1-1530-en.html
URL: http://ncmbjpiau.ir/article-1-1530-en.html
Chemistry Department, Najafabad Branch, Islamic Azad University, Najafabad, Iran
Abstract: (842 Views)
Aim and Background: HCQ is one of the auxiliary drugs for the treatment of malaria, some cancerous tumors and viruses. Targeted drug delivery systems can be used to deliver the drug to the target site, controlling the dose and reducing cell damage. In this project, a magnetic nanocomposite for drug transfer was produced and investigated.
Material and methods: PVA/GT /Fe3O4 nanocomposite was produced for HCQ drug delivery and the drug release rate of this nanocomposite was evaluated at pH 7.4 and at different times. In order to optimize the nanocomposite, the effect of Fe3O4 and maleic anhydride nanoparticles on the swelling of the nanocomposite and drug release was investigated.
Results: Drug release is highly dependent on the amount of Fe3O4 and crosslinker, which can be controlled by changing the dose of nanocomposite. The highest cumulative drug release belonged to nanocomposites containing 4% wt Fe3O4 during 6 hours (13.92%).
Conclusion: PVA/GT /Fe3O4 nanocomposites can control the release of a certain dose of HCQ drug and reduce its side effects, so it can be considered as a drug carrier for the treatment of related diseases that require clinical studies.
Material and methods: PVA/GT /Fe3O4 nanocomposite was produced for HCQ drug delivery and the drug release rate of this nanocomposite was evaluated at pH 7.4 and at different times. In order to optimize the nanocomposite, the effect of Fe3O4 and maleic anhydride nanoparticles on the swelling of the nanocomposite and drug release was investigated.
Results: Drug release is highly dependent on the amount of Fe3O4 and crosslinker, which can be controlled by changing the dose of nanocomposite. The highest cumulative drug release belonged to nanocomposites containing 4% wt Fe3O4 during 6 hours (13.92%).
Conclusion: PVA/GT /Fe3O4 nanocomposites can control the release of a certain dose of HCQ drug and reduce its side effects, so it can be considered as a drug carrier for the treatment of related diseases that require clinical studies.
Type of Study: Research Article |
Subject:
Physiology
Received: 2021/11/7 | Accepted: 2022/05/28 | Published: 2023/01/3
Received: 2021/11/7 | Accepted: 2022/05/28 | Published: 2023/01/3
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
